Advanced Search
0
PharmaCyte Biotech Inc (PMCB) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

PharmaCyte Biotech Inc (PMCB) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
  • Products Id :- GDPH207662D
  • |
  • Pages: 55
  • |
  • |
  • Region:
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

PharmaCyte Biotech Inc (PharmaCyte), formerly Nuvilex Inc, is a clinical stage biotechnology company that develops and commercializes treatments for cancer and diabetes. The company offers technology is used for the treatment of advanced and inoperable pancreatic cancer and diabetes. It develops cell-in-a-box cellulose-based live cell encapsulation technology. PharmaCyte's treatment for pancreatic cancer consists of the combination of live cells encapsulated using Cell-in-a-Box technology together with low doses of the anticancer prodrug ifosfamide. It conducts research in the areas of live cell encapsulation technology, pancreatic cancer, diabetes, cannabinoids and cancer and breast cancer, among others. PharmaCyte is headquartered in Laguna Hills, California, the US.

PharmaCyte Biotech Inc (PMCB)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

PharmaCyte Biotech Inc, Medical Devices Deals, 2012 to YTD 2018 10

PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deal Details 12

Asset Purchase 12

Nuvilex Acquires Rights To Live-Cell Encapsulation Technology For Diabetes From SG Austria 12

Partnerships 13

PharmaCyte Biotech Partners with Translational Drug Development and Clinical Network Services 13

PharmaCyte Biotech Enters into Co-Development Agreement with University of Technology Sydney 14

Licensing Agreements 15

PharmaCyte Biotech Enters into Licensing Agreement with Austrianova Singapore for Cannabis Therapies 15

PharmaCyte Biotech Enters into Licensing Agreement with Austrianova Singapore 16

Nuvilex Enters into Licensing Agreement with University of Technology Sydney 17

Equity Offering 18

PharmaCyte Biotech to Raise up to USD25 Million in Public Offering of Shares 18

PharmaCyte Biotech Raises USD1 Million in Private Placement of shares 19

Nuvilex to Raise up to USD50 Million in Public Offering of Shares 20

Nuvilex Completes First Tranche Of Private Placement Of Shares For USD 2 Million 21

Nuvilex Competes Private Placement Of Securities For USD 1.5 Million 22

Acquisition 23

Nuvilex Acquires 14.5% Stake In SGAustria, Life Science Company 23

Nuvilex Acquires Bio Blue Bird For USD 1.5 Million 24

PharmaCyte Biotech Inc-Key Competitors 25

PharmaCyte Biotech Inc-Key Employees 26

PharmaCyte Biotech Inc-Locations And Subsidiaries 27

Head Office 27

Other Locations & Subsidiaries 27

Recent Developments 28

Corporate Communications 28

Oct 10, 2017: PharmaCyte Biotech Appoints Dr. Raymond Tong to Board of Directors 28

Jul 26, 2017: PharmaCyte Biotech Appoints Dr. Linda S. Sher as Chief Medical Officer 29

Jul 10, 2017: PharmaCyte Biotech Appoints Dr. Michael M. Abecassis to Board of Directors 31

May 02, 2017: PharmaCyte Biotech Appoints Thomas Yuen to Board of Directors 32

Apr 03, 2017: PharmaCyte Biotech Appoints Dr. Mark Rabe Director of Cannabis Program Development 33

Legal and Regulatory 34

Nov 16, 2017: British Columbia Securities Commission Revokes Cease Trade Order on PharmaCyte Biotech Securities 34

Government and Public Interest 36

Feb 23, 2017: First Ever Cannabis-Based ETF to Include PharmaCyte Biotech, Abbott Laboratories, and GW Pharmaceuticals 36

Product News 37

Dec 05, 2017: PharmaCyte Biotech Announces Production of Master Cell Bank 37

Oct 17, 2017: PharmaCyte Biotech Research Identifies Enzyme Activity for Cannabinoid-Based Therapy to Fight Cancer 38

04/18/2017: PharmaCyte Biotech Discusses Future of Cannabis Research Program, Competitors and More with Program's Director 39

04/10/2017: PharmaCyte Biotech's Cannabis Research Program Sees Significant Progress in University of Northern Colorado Presentations 41

Feb 13, 2017: PharmaCyte Biotech Moves Closer to Filing IND with Naming of Comparator Arm for Upcoming Clinical Trial and Discusses Pivotal Trial Opportunity 43

01/24/2017: PharmaCyte Going Head to Head with Eli Lillys Pancreatic Cancer Drug in New Clinical Trial 45

Jan 10, 2018: PharmaCyte Announces Completion of Master Cell Bank 47

Product Approvals 48

Feb 13, 2017: PharmaCyte Biotech Moves Closer to Filing IND with Naming of Comparator Arm for Upcoming Clinical Trial and Discusses Pivotal Trial Opportunity 48

Jan 30, 2017: PharmaCyte Biotech Retains Facet Life Sciences to Guide Pancreatic Cancer Therapy Development Lifecycle with FDA 50

Jan 04, 2017: PharmaCyte Biotech Announces Pre-IND Meeting Date with FDA 51

Clinical Trials 52

Feb 21, 2017: PharmaCyte Biotech Discusses Patient Enrollment and TD2s Role in Upcoming Clinical Trial 52

Other Significant Developments 54

Feb 06, 2018: PharmaCyte Announces Completion of Preparatory Work and Commencement of Testing by Eurofins of Cells from Its Master Cell Bank 54

Appendix 55

Methodology 55

About GlobalData 55

Contact Us 55

Disclaimer 55

List of Figures

PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

PharmaCyte Biotech Inc, Medical Devices Deals, 2012 to YTD 2018 10

List of Tables

PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Key Facts, 2018 2

PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

PharmaCyte Biotech Inc, Deals By Therapy Area, 2012 to YTD 2018 9

PharmaCyte Biotech Inc, Medical Devices Deals, 2012 to YTD 2018 10

PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Nuvilex Acquires Rights To Live-Cell Encapsulation Technology For Diabetes From SG Austria 12

PharmaCyte Biotech Partners with Translational Drug Development and Clinical Network Services 13

PharmaCyte Biotech Enters into Co-Development Agreement with University of Technology Sydney 14

PharmaCyte Biotech Enters into Licensing Agreement with Austrianova Singapore for Cannabis Therapies 15

PharmaCyte Biotech Enters into Licensing Agreement with Austrianova Singapore 16

Nuvilex Enters into Licensing Agreement with University of Technology Sydney 17

PharmaCyte Biotech to Raise up to USD25 Million in Public Offering of Shares 18

PharmaCyte Biotech Raises USD1 Million in Private Placement of shares 19

Nuvilex to Raise up to USD50 Million in Public Offering of Shares 20

Nuvilex Completes First Tranche Of Private Placement Of Shares For USD 2 Million 21

Nuvilex Competes Private Placement Of Securities For USD 1.5 Million 22

Nuvilex Acquires 14.5% Stake In SGAustria, Life Science Company 23

Nuvilex Acquires Bio Blue Bird For USD 1.5 Million 24

PharmaCyte Biotech Inc, Key Competitors 25

PharmaCyte Biotech Inc, Key Employees 26

PharmaCyte Biotech Inc, Subsidiaries 27

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

PharmaCyte Biotech Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
select a license
Single User License
USD 250 INR 17835
Site License
USD 500 INR 35670
Corporate User License
USD 750 INR 53505
NEWSLETTER BY CATEGORY
FAQ
Clientele
Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...
Related Products in vertical
Company
Quick links
Other Links
Contact Us
Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

apply for job

Engage with Us

sales [@] kenresearch.com

  • Master Card
  • Visa Card
  • American Card

© Copyright 2017, KEN RESEARCH All rights reserved.

Compare